139 related articles for article (PubMed ID: 36469321)
1. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.
Cafardi J; Miller C; Terebelo H; Tewell C; Benzaquen S; Park D; Egan P; Lebovic D; Pettit K; Whitman E; Tremblay D; Feld J; Buckley S; Roman-Torres K; Smith J; Craig A; Mascarenhas J
JAMA Netw Open; 2022 Dec; 5(12):e2242918. PubMed ID: 36469321
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
6. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
Caricchio R; Abbate A; Gordeev I; Meng J; Hsue PY; Neogi T; Arduino R; Fomina D; Bogdanov R; Stepanenko T; Ruiz-Seco P; Gónzalez-García A; Chen Y; Li Y; Whelan S; Noviello S;
JAMA; 2021 Jul; 326(3):230-239. PubMed ID: 34283183
[TBL] [Abstract][Full Text] [Related]
7. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial.
Bouadma L; Mekontso-Dessap A; Burdet C; Merdji H; Poissy J; Dupuis C; Guitton C; Schwebel C; Cohen Y; Bruel C; Marzouk M; Geri G; Cerf C; Mégarbane B; Garçon P; Kipnis E; Visseaux B; Beldjoudi N; Chevret S; Timsit JF;
JAMA Intern Med; 2022 Sep; 182(9):906-916. PubMed ID: 35788622
[TBL] [Abstract][Full Text] [Related]
9. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
12. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
18. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
20. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
